TIGIT靶点，曾被誉为“下一个PD-1”，在免疫治疗领域备受瞩目。然而，其研发之路却充满坎坷，众多药企纷纷折戟。近期，阿斯利康的PD-1/TIGIT双抗药物Rilvegostomig启动了头对头帕博利珠单抗（K药）的III期研究，为TIGIT靶点带 ...

CD8-positive T cells are a critical subpopulation of MHC class I-restricted T cell and are mediators of adaptive immunity. They include cytotoxic T cells, which are important for killing cancerous ...

Priya Hays, Hays Documentation Specialists, discusses innovations and advancements in the development of personalized cancer ...

This important study provides solid evidence to support the anti-tumor potential of citalopram, originally an anti-depression drug, in hepatocellular carcinoma (HCC). In addition to their previous ...

drugs targeting TIGIT had become sought-after assets in the pharma industry, on the promise that they may inhibit anti-tumour responses that down-regulate the activity of T-cells and provide an ...

Like PD-L1, TIGIT is thought to act as a molecular brake that stops T cells from attacking tumours, and tiragolumab is currently leading the pack among drugs targeting the immune checkpoint.

Initial data demonstrate a highly differentiated clinical pharmacodynamic profile with unprecedented levels of selective CD8+ T cell activation as well as initial evidence of anti-tumor effect ...